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Abstract
Cancer is a devastating disease, being responsible for 13 % of all deaths worldwide. One of the main challenges in
treating cancer concerns the fact that anti-cancer drugs are not highly specific for the cancer cells and the “death”
of healthy cells in the course of chemotherapy treatment is inevitable. In this sense, the use of drug delivery
systems (DDS) can be seen as a powerful tool to minimize or overcome this very important issue. DDS can be
designed to target specific tissues in order to mitigate side effects. Bioabsorbable polymers, due to their inherent
characteristics, and because they can be synthesized in a variety of forms, are materials whose importance in the
DDS for cancer therapy has risen significantly in the last years. This review intends to give an overview about the
latest developments in the use of bioabsorbable polymers as DDS in cancer therapy, with special focus on
nanoparticles, micelles, and implants.
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Introduction
Nowadays, cancer is the first cause of death in industri-
alized countries and the second cause of death in devel-
oping countries [1]. The disease was the cause of 7.6
million deaths worldwide, and 12.7 million new cancer
cases are reported per year [2]. The most common types
of cancer include breast, colorectal, prostate, and lung
cancers being the last one, responsible for 1.6 million of
the deaths [3]. Radiotherapy and surgery are the most
used methods for the treatment of local and non-
metastatic cancers, whereas chemotherapy is the main
treatment for metastatic cancers. Often, the three treat-
ments are combined together. Chemotherapy is based
on the use of anti-cancer drugs that are intended to in-
hibit the fast proliferation of cancer cells, but inevitably,
the lack of selectivity will damage healthy tissues causing
adverse side effects. Additionally, due to their chemical
structure, drugs also show low half-life times in the
blood stream and a low bioavailability. These two
facts often originate the need of higher drug dose ad-
ministration, with concomitant problems related with
undesired side effects [4–6]. In this sense, the use of
drug delivery systems (DDS) can offer important
“breakthroughs” in the field of chemotherapy. In gen-
eral, a DDS allows the delivery of an active com-
pound in a controlled way (time and release rate) and
allows the maintenance of the drug concentration in
the body within a more acceptable therapeutic window
[7]. DDS can be formulated in the form of particles (mi-
croparticles, nanoparticles, micelles, liposomes) to be
administered through the common routes (e.g., oral,
pulmonary) or can in be used in the form of implants,
both injectable (e.g., gels, microparticles) and surgical
(e.g., sheets/films, foams, scaffolds) [8].
Polymers, both natural and synthetic, due to their
versatility and characteristics have been widely used
in the development of DDS. Natural polymers are
highly biocompatible and biodegradable and present
functional groups (e.g., -OH, -NH2) that can be easily
modified. Synthetic polymers, in turn, have the possibility
of being prepared with tailored compositions, and their
properties can be easily adjusted, to match a specific ap-
plication [9–11]. In particular, bioabsorbable synthetic
polymers have particular relevance in the context of DDS
since they (or their degradation products) can be metabo-
lized in the biological environment [12].
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This review intends to give an overview about the
different DDS prepared using bioabsorbable polymers in
the field of cancer therapy.
Bioabsorbable polymers in DDS
Bioabsorbable polymers can be defined as polymers that
undergo transformations in the biological environ-
ment by, for example, phagocytosis, through cellular
activity [12, 13]. The bioabsorbable materials that are
commonly used in cancer therapy are polyesters,
polyanhydrides, polyphosphoesters, polysaccharides
(e.g., chitosan, dextran, hyaluronic acid), and proteins
(e.g., albumin, gelatin).
Bioabsorbable synthetic polymers
The aliphatic polyester poly(lactic acid) (PLA), the copoly-
mer poly(lactic-co-glycolic acid) (PLGA), and poly(ɛ-
caprolactone) (PCL) (Fig. 1) are by far the most used
bioabsorbable synthetic polymers in the biomedical
field [9, 12].
PLA can be obtained either from the polycondensation
of lactic acid (LA) or by the ring opening polymerization
(ROP) of lactide. This polyester can exist in four differ-
ent morphological forms: poly(L-lactic acid) (PLLA),
poly(D-lactic acid) (PDLA), the racemic poly(D,L-lactic
acid) (PDLLA), and meso-PLA. PLLA and PDLA are
semicrystalline, and PDLLA is amorphous in nature.
Typically, these polyesters degrade by the hydrolysis of
the ester linkage, giving LA as the degradation product
[9, 14, 15]. In biomedical applications, only PLLA and
PDLLA have been extensively studied. PDLLA presents
a faster degradation time than PLLA, being more suit-
able for drug delivery applications [9].
PLGA is obtained through the copolymerization of LA
(or lactide) and glycolic acid (GA) (or glycolide), and the
properties (physical and biodegradation) of the copo-
lyester can be easily tailored by changing the relative
amounts of monomers in the final copolymer. The
products of degradation are existing metabolites (LA
and GA) of the human body [12, 16].
PCL is synthesized by the ROP of ɛ-caprolactone (ɛ-CL).
It is a semicrystalline polymer with a low melting point
range (59–64 °C), being suitable for the preparation of
blends with other polymers or ceramic materials. Since
PCL degrades slowly, it is mainly used in DDS that require
long release profiles (e.g., more than 1 year). Nevertheless,
if the ɛ-CL is copolymerized with LA or GA, a material
that degrades faster is obtained. Upon degradation, PCL re-
leases products with a less acidic character when compared
to those released by PLA and PLGA [17].
Poly(hydroxyalkanoates) (PHAs) are aliphatic polyesters
synthesized by microorganisms from various substrates
used as carbon sources, under conditions of limiting nu-
trients [18]. Figure 2 shows the general structure of PHAs.
Until today, more than 150 different types of PHAs have
been identified. These polyesters can be classified accord-
ing to the number of carbons in the repeating unit in short
chain length PHAs (3–5 carbon atoms) or in medium
chain length PHAs (6–14 carbon atoms) [18, 19]. In the
biomedical field, poly(3-hydroxybutyrate) (PHB) and the
copolymers poly(3-hydroxybutyrate-co-4-hydroxybutyrate)
(PHB4HB) and poly(3-hydroxybutyrate-co-3-hydroxyhex-
anoate) (PHBHHx) have attracted particular attention due
to their excellent biocompatibility. PHB degrades slowly in
vivo giving as degradation product D-3-hydroxybutyric
acid, which is a component of blood plasma, serving as an
energy reserve of extra-hepatic tissues during fasting,
being well tolerated in vivo [20]. PHBHHx is very biocom-
patible in vivo since its degradation by-products,
oligo(3-hydroxybutyrate) (OHB) and oligo(3-hydroxy-
butyrate-co-3-hydroxyhexanoate) (OHBHHx), present
positive effects on cell growth [21, 22].
Polyanhydrides are a class of surface-eroding polymers,
and their hydrolysis rate can be controlled by the nature
of the monomers (aliphatic or aromatic) used in the syn-
thesis; aliphatic polyanhydrides degrade in days, whereas
their aromatic counterparts degrade slowly over years.
Thus, the careful selection of the monomers in the
synthesis allows the preparation of polyanhydrides with a
wide range of erosion rates. This class of polymers can be
synthesized by different methods (melt polycondensation,
Fig. 1 Structures of the aliphatic polyesters: a PLA, b PLGA, and c PCL Fig. 2 General structure of PHAs
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ROP, interfacial polycondensation), but only the melt poly-
condensation allows the synthesis of these polymers with
high molecular weight [23]. Polyanhydrides have been
used as DDS, but attention should be paid regarding the
drug that is going to be encapsulated to avoid undesirable
reactions with drugs containing free amino groups or
other nucleophilic groups, especially if the encapsulation
occurs at high temperatures [12]. The most extensively
studied polyanhydride copolymer is poly[(1,3-bis-car-
boxyphenoxypropane)-co-(sebacic anhydride)] (Fig. 3).
This copolymer is approved by the Food and Drug
Administration (FDA) for use in a biomedical device
for the treatment of brain cancer that is marketed
under the name Gliadel® Wafer [24].
Polyphosphoesters are an additional class of bioabsorb-
able polymers containing phosphorous (Fig. 4), developed
in the 1970s by Lapienis and Penczek [25].
This class of polymers, due to the presence of the phos-
phoester bonds in their structure, is highly biocompatible.
Depending on the type of functional group linked to the
phosphorous atom, polyphosphoesters can be divided into
polyphosphites (R1 = H), polyphosphonates (R1 = alkyl/aryl
group), and polyphosphates (R1 = aryloxy/alkyloxy group)
[26, 27]. The choice of the R1 and R groups allows the
change of the polymers’ physico-chemical properties.
Various synthetic routes including ROP, polycondensation,
and transesterification are used to synthesize polypho-
sphoesters [27]. The degradation of polyphosphoesters
occurs by hydrolytic and enzymatic cleavage of the
phosphorous-oxygen bonds, giving phosphates, alcohols,
and diols as degradation by-products. Due to the pentava-
lency of the phosphorous atom, the polyphosphazenes are
able to chemically bind drugs or proteins. This is an inter-
esting feature presented by this family of polymers since it
enables the preparation of new polymer pro-drugs, with
good in vivo compatibility [10]. Polyphosphoester-based
microspheres have been used as DDS for paclitaxel (PTX)
and are commercialized under the name Paclimer® [24].
Natural polymers
Natural polymers can be divided into two main classes:
proteins and polysaccharides. From a structural point of
view, proteins are high molecular weight molecules in
which α-amino acid residues are linked together by
amide linkages and usually present a tridimensional
folded structure [7].
Albumin and gelatin are the proteins with more rele-
vance for the preparation of DDS for cancer therapy. Al-
bumin is the most abundant protein in the human blood
plasma, accounting for 50 % of its total mass. It presents
a molecular weight of about 66.5 kDa and a diameter of
7.2 nm. Human serum albumin (HSA) has a multitude
of functions in the human body [10, 11]. Among those,
it is possible to mention the following: solubilization of
long chain fatty acids, binder for bilirubin (resulting
from heme breakdown), transport of metal ions (cop-
per(II), nickel(II), calcium(II), and zinc (II)) in the blood
stream, and major responsibility for colloid osmotic
pressure of the blood, and upon hydrolytic breakdown,
the resulting α-amino acids provide nutrition to the
nearby tissues [28]. Albumin is a hydrosoluble protein, is
stable in a pH range of 4 to 9, and can be heated at 60 °C
for up to 10 h without deleterious effects. Since this pro-
tein is biodegradable, non-toxic, and non-immunogenic, it
can be seen as an ideal candidate for DDS [10, 11, 28]. In
the development of DDS for cancer therapy, the use of
albumin can bring some advantages since this protein is
used by the proliferating tumor cells for their nutrition,
being readily taken up by a fluid phase endocytosis,
followed by lysosomal breakdown. The α-amino acids
resulting from the lysosomal digestion are used by the
cancer cells as a source of nitrogen and energy [29]. In the
market, there is already an injectable formulation of PTX-
albumin nanoparticles, known as Abraxane®, that has been
used in the treatment of breast cancer [28].
Gelatin is a protein obtained by the thermal denaturation
of animal collagen, in which the triple helix of collagen is
broken giving water-soluble strains (Fig. 5) [30, 31].
If collagen is subjected to an acidic treatment before
denaturation, type A gelatin, with an isoelectric point
(IP) of 5, is obtained. In turn, if an alkaline treatment is
used, type B gelatin, with an IP of 9, is obtained [31].
Gelatin is a polyampholyte whose structure comprises
Fig. 3 Chemical structure of poly[(1,3-bis-carboxyphenoxypropane)-
co-(sebacic anhydride)]
Fig. 4 Generic structure of a polyphosphoester
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cationic (ca. 13 % in the total structure) and anionic
groups (ca. 12 % in the total structure), along with the
hydrophobic groups (ca. 11 % of the total structure). The
positively charged groups are due to the presence of lysine
and arginine residues, the negatively charged groups came
from glutamic and aspartic acid, and the hydrophobic
chain comprises residues of leucine, isoleucine, methio-
nine, and valine. Glycine, proline, and hydroxyproline
form the remaining part of the protein chain (Fig. 6) [30].
Gelatin undergoes a sol-gel transition in aqueous
solution when the temperature is lowered below 35 °C.
Because of its biodegradability and biocompatibility,
gelatin has been used in the development of DDS for
different biomedical applications, namely cancer ther-
apy [30, 32].
Polysaccharides are high molecular weight compounds,
composed by monosaccharide repeating units. The mono-
saccharide units are linked together by O-glycosidic bonds
that can occur on any hydroxyl group of the monosacchar-
ide, yielding linear and branched structures. These biopoly-
mers can have different origins, namely algal origin (e.g.,
alginate and carrageenan), plant origin (e.g., cellulose,
pectin, and guar gum), and animal origin (e.g., chitosan,
hyaluronic acid, chondroitin, and heparin) [33]. The hydro-
phobicity, solubility, and physico-chemical properties of
the polysaccharides can be easily modified by different
reactions, namely oxidation, sulfation, esterification, amida-
tion, or by grafting methods [34]. In the context of cancer
therapy, hyaluronic acid, chitosan, and dextran (Fig. 7) are
the most explored polysaccharides.
Hyaluronic acid is a linear polysaccharide that belongs
to the glycosaminoglycan family and is composed of
alternating disaccharide units of β-1,3-N-acetyl-D-glu-
cosamine and α-1,4-D-glucuronic acid connected by
β(1→ 3) linkages. Its molecular weight can reach a few
million Da [9, 10, 35]. This polysaccharide is the most
abundant macromolecule in the intercellular matrix of
conjunctive tissues such as vitreous humor, cartilage,
umbilical cord, and synovial fluid [35, 36]. Regarding the
applicability of hyaluronic acid in biomedical applications,
several advantages can be pointed out: water-solubility,
biodegradability, biocompatibility, non-toxicity, non-
immunogenicity, and ease of chemical modification [33].
Another important feature of hyaluronic acid is its binding
capacity to CD144 and CD168 (also known as receptor
for hyaluronan-mediated motility, RHAMM) receptors,
making it suitable to target cells that overexpress these re-
ceptors as cancer cells (squamous cell carcinoma, ovarian,
colon, stomach, glioma, and many types of leukemia,
lymphoma, and multiple myeloma) [33, 37–39].
Chitosan is a cationic polysaccharide obtained from
the alkaline deacetylation of chitin, a polysaccharide
widely found in Nature. It is composed by units of
β(1→ 4)-2-amido-2-deoxy-D-glucan (D-glucosamine)
and β(1→ 4)-acetoamido-2-deoxy-D-glucan (N-acetyl
glucosamine) [33, 35]. The ratio between the D-glucosa-
mine and N-acetyl glucosamine in the chitosan chain
represents the deacetylation degree and usually presents
values between 70 and 90 %. The deacetylation degree is
a very important parameter since it controls the solubil-
ity, hydrophobicity, and the chitosan ability to interact
with polyanions [40–42]. Chitosan is insoluble in water
and in organic solvents but can be dissolved in slightly
acidic aqueous solutions. The insolubility of chitosan is
attributed to its rigid and highly crystalline structure due
to the hydrogen bonds established between the primary
amino groups and the acetoamido groups. A possible
strategy to overcome this situation is the functionali-
zation of the primary amino groups with other mole-
cules (e.g., phthalic anhydride) in order to disrupt the
crystalline structure [40]. Nevertheless, chitosan’s bio-
compatibility and biodegradability, along with its mucoad-
hesive properties, make it an interesting and widely used
polymer for DDS [33, 35]. Another interesting and im-
portant feature is that chitosan revealed per se anti-cancer
properties both in vitro and in in vivo [43].
Dextran is a water-soluble polysaccharide composed
by α-1,6-linked D-glucopyranose units with branches
extending mainly from the α-1,3- and occasionally from
Fig. 5 Schematic representation of the thermal denaturation of
collagen (adapted from [7])
Fig. 6 Structure of gelatin
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the α-1,2- and α-1,4- positions. It is produced by differ-
ent bacteria from sucrose through the action of the en-
zyme dextransucrase. Dextran can present different
molecular weights, molecular weight distributions, and
degrees of branching depending on the conditions and
bacterial strain used in its production [44, 45]. Dextran is
easily biodegraded by the action of natural enzymes like
dextran-(1,6)-glucosidase and dextranase. Additionally, it
also shows good biocompatibility, non-immunogenicity,
and non-antigenicity. Other important characteristics of
dextran are related with its non-cell-binding ability and
the capacity to resist protein adsorption, making it useful
for intravenous administration [39, 44].
Polymer-based DDS for anti-cancer therapy
Nanocarriers
Nanoparticles and micelles are undoubtedly the most
used nanocarriers for anti-cancer therapy, and to
maximize their utility and efficacy, they should obey a
set of requisites. Thus, to be effective in cancer therapy,
the nanocarriers should (i) increase the drug concentra-
tion in the tumor by passive or active targeting, (ii) de-
crease drug concentration in healthy tissues, (iii) improve
the drug solubility to allow intravenous administration,
(iv) release a minimum of drug during transit, (v) enhance
the drug targeting specificity, (vi) improve internalization
and intracellular delivery, (vii) protect the active
compound against biochemical degradation, and (viii) be
biocompatible [46].
Other important characteristics of nanocarriers that
affect the drug release behavior are the size, composition,
shape, surface charge and roughness, and the hydrophobic
or hydrophilic nature [6]. Regarding the size, it is com-
monly accepted that the nanocarriers should not exceed
the 400 nm to escape from the mononuclear phagocyte
system (MPS) and be able to achieve extravasation into
tumors by the enhanced permeability and retention (EPR)
effect, which is more effective for nanocarriers with diam-
eters below 200 nm [4]. Concerning the surface of the
DDS, it must be hydrophilic and neutral to avoid plasma
protein (opsonins) adsorption, which will delay the attack
by the reticuloendothelial system (RES), increasing the
blood circulation time.
Nanoparticles
Nanoparticles can be divided into two categories: nano-
spheres (matrix system) and nanocapsules (reservoir sys-
tem). Nanospheres correspond to a solid polymer matrix;
in this case, the active compound can be either molecu-
larly dissolved or heterogeneously dispersed within the
matrix. Nanocapsules are composed by a core and a shell;
typically, the drug is in a cavity that is surrounded by the
polymer shell [47]. Along the years, polymeric nanoparti-
cles have proved to be efficient carriers for the sustained
and prolonged release of anti-cancer drugs, mainly
because the drug release behavior from the nanoparticles
can be easily modulated by the type of polymer used [48].
The nanoparticles can be prepared by different tech-
niques, namely emulsification, coacervation, nanoprecipi-
tation, salting-out, dialysis, and electrospray [7].
Among the bioabsorbable synthetic polymers used to
prepare nanoparticles for cancer treatment, PLGA is by
far the most used. In 2011, Acharya and Sahoo published
an excellent review about the use of PLGA nanoparticles
Fig. 7 Structures of a hyaluronic acid, b chitosan, and c dextran
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in cancer therapy [49]. In 2012, Danhier et al. [50] devoted
part of their review article entitled “PLGA-based nanopar-
ticles: An overview of biomedical applications” to the use
of PLGA nanoparticles in cancer treatment. Along the last
years, PLGA-based DDSs have been developed and tested
as carriers of different drugs to treat different types of
cancer, viz., pancreatic [51], osteosarcoma [52], breast
[53–55], lung [56], and prostate [57].
Zhou et al. [58] prepared PLGA nanoparticles for the
delivery of small interfering ribonucleic acid (siRNA) in
tumors. By sequential steps, the authors managed to give
the nanoparticles a set of controllable synergistic func-
tions, namely (i) stabilization and controlled release of
siRNA; (ii) encapsulation of siRNA for gene knockdown;
and enhancement (iii) of endosomal escape, (iv) of siRNA
potency, and (v) of circulatory time, (vi) cell penetration,
and (vii) tumor targeting. The in vivo results showed that
the PLGA-based DDS was effective in controlling the
growth of tumor and in prolonging the knockdown of the
PLK1 gene, which is essential for mitosis. This gene is
overexpressed in many types of cancer, being associated
with tumorigenesis. More recently, Wang et al. [59]
co-encapsulated doxorubicin (DOX) and epidermal
growth factor receptor (EGFR) siRNA in PLGA nano-
particles, in which the angiopep-2 (ANG) was conju-
gated. ANG is a brain-targeted peptide, and its use
could bring advantages in overpassing the blood brain
barrier (BBB) that is known to restrict the access of
drugs to the brain. The DDS was tested in vitro making
use of a U87MG cell line (human primary glioblastoma
cell line). It was found that it was able to efficiently release
the DOX and siRNA, contributing to an inhibition of the
cell growth, apoptosis, and EGFR silencing. The in vivo
tests showed that DDS was capable of crossing the BBB,
and the therapy using both EGFR siRNA and DOX con-
tributed to extend the survival time of the U87MG-
glioma-bearing mice.
Schleich et al. [60] developed theranostic PLGA nano-
particles loaded with PTX and superparamagnetic iron
oxide (SPIO) (a contrast agent for magnetic resonance im-
aging), using the emulsion-diffusion-evaporation method.
The nanoparticles were spherical in shape with a diameter
of 240 nm. The in vivo anti-tumor efficacy was tested with
CT26 (colon carcinoma cells)-tumor-bearing mice, and
the results showed that the loaded nanoparticles were ef-
fectively uptaken by the CT26 cells and were able to delay
the regrowth of the CT26 tumor.
Shi et al. [61] studied the effect of conjugating vascular
endothelial growth factor receptor (VEGFR) to the
surface of PLGA nanoparticles encapsulating PTX.
VEGFR can be considered as an ideal targeting moiety
in cancer treatment, since it is overexpressed on the
surface of a variety of tumor cells and plays a key role in
the mitosis and angiogenesis processes. The PLGA
nanoparticles were prepared by the emulsion-solvent
evaporation method, and then, the VEGFR was conjugated
to the nanoparticles’ surface. The results showed that
16.6 wt.% of VEGFR was conjugated to the nanoparticles’
surface. The diameters of the particles ranged from
390 nm (for blank nanoparticles) to 710 nm (for particles
containing VEGFR and PTX). The anti-tumor activity of
PTX encapsulated in the VEGFR-PLGA nanoparticles was
studied in vitro making use of 7721 human hepatocarci-
noma cells and A549 human lung cancer cells. The results
showed that the PTX-loaded VEGFR-PLGA nanoparticles
have a high inhibitory activity of tumor growth when
compared with native PTX or with PTX-loaded PLGA
nanoparticles.
Very recently, Iodice et al. [62] encapsulated gold nano-
particles (AuNPs; 6 nm) in PLGA nanoparticles coated
with a lipid poly(ethylene glycol) (PEG) monolayer and
used the ensuing nanostructures in photothermal therapy.
The nanostructures presented diameters ranging from 100
to 180 nm, being the size dependent on the amount of
gold. The cytotoxic effect of these nanostructures was
tested in 2D monolayers of breast cancer cells (SUM-159)
and 3D tumor spheroids of glioblastoma multiform cells
(U87MG). The overall results suggest that the encapsula-
tion of the AuNPs in the coated PLGA nanoparticles
improved the photothermal ablation.
Although less used than PLGA, PLA-based nanoparticles
also showed to be promising as anti-cancer drug DDS.
Jing et al. [63] prepared theranostic DOX-loaded PLA
nanoparticles (Fig. 8) by a nanoemulsion method,
followed by the conjugation of a Mn-porphyrin on the
surface of the nanoparticles.
The in vitro release studies showed that the nanoparti-
cles are sensitive to pH; at neutral pH, the DOX release
was slow, while in acidic medium, the release was sig-
nificantly faster. The results also demonstrated that the
nanoparticles are effective in inhibiting the growth of
HeLa and HT-29 cells. Additionally, the nanoparticles
were subjected to a magnetic resonance imaging (MRI)
scanning analysis, and it was shown that the nanoparti-
cles had higher longitudinal relaxivity in water than the
Mn-porphyrin, making them excellent candidates to be
used in T1-weighed MRI. Also in the field of theranostic
PLA nanoparticles, Du et al. [64] reported the prepar-
ation of PLA nanocarriers to release endostar, a recom-
binant human statin that has been shown to inhibit
tumor angiogenesis. The surface of the nanoparticles
was conjugated with a peptide, GX1, which is a tumor
vasculature endothelium-specific ligand that holds great
potential as a targeted vector and anti-angiogenic agent.
Additionally, the nanoparticles were labeled with the
near-infrared dye IRDye 800CW to allow the monitori-
zation of the biodistribution and tumor-targeting efficacy
of nanoparticles by means of fluorescence molecular
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imaging. Colorectal cancer was used as the model
disease. The in vivo tests performed on colorectal-
tumor-bearing mice showed that the endostar-loaded nano-
particles were more effective in treating the tumor than the
native endostar. The presence of the dye was useful to
follow the biodistribution of the nanoparticles in vivo.
Very recently, Yang et al. [65] developed a DDS based
on PLA nanoparticles for the treatment of lung cancer
metastasis. The nanoparticles encapsulating docetaxel
(DTX) were prepared by the single emulsion method,
and a targeting peptide was conjugated on their surface.
The targeting peptide, screened from lung carcinoma stem
cells, showed a high specific-binding ability to pulmonary
adenocarcinoma tissue. The anti-metastatic efficacy of the
nanoparticles was tested in vivo making use of a nude
mice model of liver metastasis. The results revealed that
the peptide had a key role in the anti-metastatic efficacy of
the nanoparticles.
Natural polymers due to their inherent advantages are
also interesting candidates to prepare nanoparticles for
anti-cancer drug delivery [39]. In recent years, albumin-
based nanoparticles have been prepared and tested as
DDS in different types of cancer. Ji et al. [66] prepared
albumin nanoparticles decorated with arginylglycylaspar-
tic acid (RGD) to be used as DDS in the treatment of
pancreas cancer. RGD was bound to the nanoparticles’
surface with the aim of targeting integrin αvβ3, which is
expressed in pancreatic tumor cells. The nanoparticles
were prepared by the desolvation-crosslinking method,
conjugated with RGD and loaded with fluorescein iso-
thiocyanate (FITC), in order to trace their biodistribu-
tion. Gemcitabine was used as the anti-cancer drug.
The in vitro tests, conducted on BxPC-3 cells, showed
that the presence of RGD at the surface of the nano-
particles led to a higher intracellular uptake when
compared with the nanoparticles without the tripep-
tide. The nanoparticles, loaded with gemcitabine, have
shown improved anti-tumor efficacy, both in vitro
and in vivo.
Recently, Bhushan et al. [67] reported the encapsula-
tion of niclosamide in albumin nanoparticles, using the
desolvation method, and tested the efficacy of the result-
ing DDS in breast cancer and lung cancer cell lines. The
in vitro tests showed that the nanocarrier improved
significantly the tumor inhibition capacity of the drug by
inducing a significant amount of apoptosis in the treated
cancer cells.
In a very interesting contribution, Mocan et al. [68]
encapsulated AuNPs in albumin carriers and used the
ensuing system in the photothermal treatment of liver
cancer. The results indicate that the nanoparticles were
selectively internalized by the HepG2 cells, meaning this
internalization was mediated by the gp60 receptors’
targeting. It was also shown that after irradiation, the
photoexcitation of the nanoparticles exhibited a higher
apoptosis capacity.
Fig. 8 Representation of the PLA nanoparticle developed by Jing et al. (adapted from [63])
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Gelatin is another protein that has been formulated as
nanoparticles for cancer therapy [30]. Lee et al. [69] pre-
pared a tumor-targeted siRNA delivery system making
use of this natural polymer. Since gelatin has a low bind-
ing affinity to siRNA, the authors functionalized both
the siRNA (in the form of a polymer, poly-siRNA)
and gelatin with thiol groups. Under the optimized
conditions, the siRNA was covalently linked to gel-
atin, by disulfide bonds, and the nanoparticles were
formed. The results showed that nanoparticles were ef-
fective in protecting the siRNA from enzymatic degrad-
ation and were able to release siRNA when exposed to
reductive environments. The efficacy of the nanoparticles
as DDS for cancer therapy was tested in red fluorescence
protein (RFP)-expressing melanoma cells. It was found
the delivery system was efficient in down-regulating the
targeted gene expression. The in vivo tests showed that
the tumor accumulation was more effective for the nano-
particles than for the naked poly-siRNA. Additionally, the
nanoparticles induced tumor RFP gene silencing in vivo,
without inducing significant toxicity.
Xu et al. [70] investigated the in vivo biodistribution
and targeting potential of three groups of type B gelatin
nanoparticles (thiolated nanoparticles, thiolated nano-
particles modified with PEG, and thiolated nanoparticles
modified with PEG bearing a EGFR-targeting peptide),
in human pancreatic carcinoma (Panc-1)-bearing SCID
Beige mice. The results revealed that EGFR-targeted
nanoparticles show an enhancement of the targeting effi-
ciency. Driven by the excellent results of biodistribution
and accumulation in tumors, the same authors used
these particles as DDS for gemcitabine, a widely used
chemotherapeutic for the treatment of pancreas cancer
[71]. Long et al. [72] encapsulated DOX in thiolated gel-
atin nanoparticles bearing the EGFR-targeting peptide
and studied their potential as DDS for lung cancer. The
in vitro tests conducted on EGFR overexpressing A549
and H226 lung cancer cells revealed that the nanoparticles
were internalized by the cells via a receptor-mediated
endocytosis. The inhibition of the tumor growth was
dependent on the dose of nanoparticles used. The in vivo
anti-tumor efficacy was evaluated in A549-tumor-cell-
bearing nude mice using inhalation as the administration
method. The results showed that the EGFR-bearing nano-
particles allowed maintaining the DOX concentration in
the lungs at a high level, even after 24 h of administration.
Moreover, the nanoparticles cause a high percentage of
tumor inhibition (90 %), when compared to native DOX.
A mice survival percentage of 100 %, during the 2 weeks
of the tests, was also observed.
Among the polysaccharides, chitosan is, by far, the
most used to formulate nanoparticles for cancer therapy
[73]. This fact can be related with its anti-cancer proper-
ties, already proved both in in vitro and in in vivo
studies [43, 74]. In 2015, two reviews about the use of
chitosan nanoparticles in tumor-targeted drug delivery
were published [75, 76].
Dextran is another polysaccharide used in the prep-
aration of nanoparticles or as a coating for magnetic
nanoparticles for anti-cancer DDS purposes. Sagnella
et al. [77] prepared dextran nanoparticles bearing al-
dehyde functionalities that were able to form an acid labile
linkage with DOX. The anti-cancer efficacy of the devel-
oped DDS was tested in vitro making use of both (2D)
SK-N-BE(2) monolayers and (3D) SK-N-BE(2) tumor
spheroids. The results show that the nanoparticles were
rapidly and effectively internalized by the (2D) SK-N-
BE(2) monolayers. Regarding the tumor spheroids, the re-
sults indicate that the nanoparticles were able to penetrate
deeper in the solid tumor when compared with DOX
alone. Very recently, dextran nanoparticles were used to
encapsulate micro ribonucleic acids (miRNAs) (miR-199a-
3p and miR-let-7a) that can act as a chemotherapeutic
agent. The miRNAs were encapsulated in lipid-modified
dextran nanoparticles, and the anti-cancer efficacy of the
DDS was tested with two different osteosarcoma lines,
viz., KHOS and U-2OS. The results showed that the miR-
NAs were successfully delivered to the tumor cells and
effectively inhibit the growth and proliferation of the
osteosarcoma cells in vitro [78]. Peng et al. [79] used
dextran-coated superparamagnetic iron nanoparticles
(SPIONs) as DDS for DOX. The complex DOX-
nanoparticles showed a pH-dependent drug release, being
faster at pH values below the physiologic pH. The in vivo
tests, carried out under an external magnetic field, per-
formed on a rabbit VX2 liver tumor model showed that
the nanoparticles were more effective in inhibiting the
tumor growth and in increasing the animal survival rate
than free DOX.
Another interesting strategy that has been used is the
preparation of nanoparticles making use of both syn-
thetic and natural polymers. For instance, Zhou et al.
[80] prepared nanoparticles based on poly(ɛ-caprolac-
tone) (PCL)-grafted galactosylated chitosan to be used as
a carrier for curcumin. The nanoparticles were prepared
through the ionotropic gelation method, using tripoly-
phosphate as the gelification agent. The encapsulation
efficiency of the nanoparticles was between 25 and 80 %,
with particle sizes ranging from 110 to 140 nm. The
most promising result in terms of release behavior
(sustained release) was observed for the copolymer
10 % galactosylated and with PCL weight percentages
below 40 %. The nanoparticles were effectively upta-
ken by the human hepatocellular carcinoma (HepG2)
cells, confirming the hepatocyte-targeting feature of
the DDS. The nanoparticles showed best results in
terms of inducing apoptosis and necrosis of the
HepG2 cells than free curcumin.
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Micelles
Micelles are nanosized (10–100 nm) aggregates of
amphiphilic copolymers, comprising a hydrophobic core,
in which a poorly water-soluble drug can be loaded, and
a hydrophilic shell (or corona), that allows the load of
hydrophilic drugs and provides stability to the micelle
[81, 82]. The micelles are obtained when the concentra-
tion of amphiphilic copolymer in aqueous medium
reaches the critical micelle concentration (CMC). Above
the CMC, the formation of the micelles is spontaneous
and driven by the dehydration of the hydrophobic part
of the polymer. In addition, the formation of van der
Waals bonds allows the hydrophobic polymers to join
and form the micelle core [83]. Typically, the amphi-
philic blocks can have different designs: A-B (diblock
copolymers), A-B-A (triblock copolymers), and grafted
copolymers (Fig. 9).
The final characteristics of the micelles can be easily
modulated by choosing the blocks that will comprise the
block copolymer. The hydrophilic block, for instance,
besides conferring stabilization to the micelles can also
be used to increase the blood circulation time. PEG is by
far the most used hydrophilic block in polymeric
micelles, since it is highly hydrophilic, is an efficient
structural stabilizer, and is biocompatible [84, 85].
There are several advantages of polymeric micelles
that make them attractive nanocarriers for cancer
therapy. Micelles can solve the solubility issues of a vast
part of chemotherapeutics, which are hydrophobic in na-
ture, because they can accommodate this type of drugs
in their hydrophobic core. The size presented by the mi-
celles is too large for extravasation from normal vessels
walls and renal excretion but allow extravasation from
tumor blood vessels. An enhanced EPR effect, which is
crucial for passive targeting, is also observed when
micelles are used. Additionally, micelles can change the
drug internalization route decreasing the P-glycoprotein
(P-gp) efflux effect, which acts as a mechanism of resist-
ance of some types of cancers to treatment with some
drugs [85, 86].
The interest and the importance of this type of carriers in
the field of cancer treatment are exhibited on the seven for-
mulations that are currently under clinical trials (Table 1).
Besides the micelles that are currently under clinical
trials, many others have been developed during the last
years [89]. Micelles can have other “functions” beyond
carrying the chemotherapeutic agent that could enhance
their performance regarding anti-cancer activity.
These carriers can be formulated to be stimuli-re-
sponsive [90–92] or to bear a targeting ligand at the sur-
face, making them able to target a specific tumor [93–95].
Micelles can also be used for theranostic purposes as
reported in the literature [96, 97]. Amphiphilic block co-
polymers based on PEG polyesters (PLA, PLGA, PCL) are
clearly the most studied materials in the formulation of
micelles [98]. However, other materials can be included;
other materials in the block copolymer or other materials
can be used to prepare polymeric micelles towards cancer
therapy. In a very interesting contribution, Zhang et al.
[99] prepared a pH-responsive triblock copolymer, viz.,
poly(ethylene glycol) methyl ether-b-(poly(lactic acid-co-
poly(β-amino ester))) (MPEG-b-(PLA-co-PAE)) with
different PLA/PAE ratios, and used it as a DDS for DOX
(Fig. 10).
The CMC of these structures in aqueous solution ranged
from 1.2 to 9.5 mg/mL, and the values have shown to be
dependent on the amount of PLA in the copolymer, being
lower for higher amounts of the polyester. The DOX load-
ing was about 18 %, and the in vitro release results showed
that the release of the drug was significantly accelerated
when the pH decreased from 7.4 to 5. This result was at-
tributed to a looser micellar structure due to the proton-
ation of the PAE moieties. The in vitro cytotoxicity tests
carried out on a HepG2 cellular line showed that the
unloaded micelles do not induce cytotoxicity, contrarily
to what was observed with the loaded DOX micelles.
Kim et al. [100] used micelles composed by poly(ethylene
oxide)-b-poly(3-hydroxybutyrate)-b-poly(ethylene oxide)
(PEO-PHB-PEO) triblock copolymers to encapsulate DOX.
The incorporation of the drug in this copolymer is
Fig. 9 Different designs of the amphiphilic copolymers used in the preparation of micelles
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enhanced due to the hydrophobicity of the PHB central
block that can lead to more stable micelles with high drug
encapsulation efficiencies. The distribution and cytotoxicity
of DOX-loaded PEO-PHB-PEO micelles was evaluated on
a monolayer culture of SiHa human cervical carcinoma
(HeLa) cells and on 3DSiHa multicellular spheroids
(MCS). In order to understand the mechanism of micelles’
cell uptake and penetration, fluorescent-labeled PEO-
PHB-PEO micelles were prepared and the in vivo anti-
proliferative activity was studied in nude mice models.
The results demonstrated that the micelles improved the
efficiency of DOX penetration in 3D MCS cultures with
effective cell killing, showing to be promising devices to
deliver DOX for cancer therapy.
Cuong et al. [101] synthesized a star-shaped PCL that
was further extended with a terminal block of poly(ethyl
ethylene phosphate) (PEEP) to yield a PCL-PEEP star-
shaped copolymer. The copolymer showed the ability to
form micelles in aqueous solutions and was used to
encapsulate DOX (Fig. 11).
The in vitro release test showed that DOX was delivered
in a pH-dependent manner, being faster at pH = 5.4 than
at physiological pH. The DOX-loaded micelles presented
enhanced cytotoxicity for both drug-sensitive and drug-
resistant human breast cancer cell lines (MCF-7). The
evaluation of the cellular uptake of the DOX-loaded mi-
celles was done by means of confocal microscopy. A
strong fluorescence in the cytoplasm of the cells indicates
that the micelles were internalized through endocytosis.
Interestingly, the drug-resistant cells showed higher cellu-
lar uptake than their drug-sensitive counterparts.
Transferrin (Tf)-conjugated polyphosphoester hybrid
micelles loaded with PTX were prepared by Zhang et al.
[102], and their in vitro and in vivo brain-targeting
ability was studied. The micelles were formed from a
blend of the copolymer PCL-co-PEEP with a maleimide-
PCL-PEG copolymer (needed for the attachment of Tf)
by the dialysis method. The micelles had diameters of
ca. 87 nm, high drug entrapment efficiency (ca. 89.9 %),
and caused negligible hemolysis. The release tests
showed that PTX can be delivered in a sustained manner
over a period of 72 h. The in vitro cellular uptake tests
were carried out with brain microvascular endothelial
cells (BMECs), since they closely represent the barrier
property of BBB in vivo. BBB highly express the Tf re-
ceptor, and because of that, the presence of Tf could me-
diate the transport of micelles across the BBB. The
results indicated that the cellular uptake by the Tf-
conjugated micelles was almost twofold higher than that ob-
served for the micelles without Tf. The anti-cancer activity
Table 1 Polymeric micelles in clinical trials for cancer therapy [4, 83, 86–88]
Polymeric micelle Block copolymer Drug Diameter (nm) Therapeutic purpose Clinical phase
Genexol-PM™ MonomethoxyPEG-b-PDLLA PTX 20–50 Metastatic breast cancer IV
Advanced urothelial cancer II
Advanced head and neck cancer II
Advanced non-small-cell lung cancer II
Ovarian cancer I
Advanced or metastatic pancreatic cancer II
Nanoxel-PM™ MethoxyPEG-b-PDLLA DTX 25 N.A. I
NK012 PEG-b-Poly(glutamic acid) SN-38 20 Breast cancer II
NK105 PEG-b-Poly(aspartic acid) PTX 85 Advanced stomach cancer/breast cancer III
NK911 PEG-b-Poly(aspartic acid) DOX 40 Various solid tumors II
NC-4016 PEG-b-Poly(glutamic acid) Oxaliplatin 30 Various solid tumors I
NC-6004 PEG-b-Poly(glutamic acid) Cisplatin 30 Pancreatic cancer III
NC-6300 PEG-b-Poly(aspartate-hydrazone) Epirubicin 60 Various solid tumors I
Fig. 10 Structure of the MPEG-b-(PLA-co-PAE)
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of the Tf-conjugated micelles was evaluated in vivo using
U87MG-glioma-bearing mice, and the results were very
promising; the micelles effectively accumulated in the brain
tumor and showed stronger anti-glioma capacity than
Taxol®, a chemotherapeutic widely used in glioma treatment.
Moreover, an increase of 6 days in the mean survival time of
the mice was observed for the group treated with the Tf-
conjugated micelles, when compared with Taxol®.
Very recently, Zhang et al. [103] prepared an
amphiphilic block terpolymer poly(2-ethylbutoxy phospho-
lane)-b-poly(2-butynylphospholane)-g-poly(ethylene glycol)
(PBEP-b-PBYP-g-PEG) (Fig. 12) and used it to formulate
uncrosslinked and crosslinked micelles (shell crosslinked
knedel (SCK)-like nanoparticles) for the encapsulation of
PTX. The SCKs were obtained by the micelles’ shell cross-
linking through a thiol-yne “click chemistry”.
The in vitro release tests showed that the SCKs provided a
slower release PTX when compared with the uncrosslinked
micelles. The anti-tumor efficacy of the micelles and SCKs
were tested against osteosarcoma cell lines (CCH-OS-O and
SJSA) that are known to metastatize in the lungs. The in
vitro tests showed that the micelles and SCKs had similar cy-
totoxicities to the commercially available Taxol-mimicking
formulation. The in vivo biodistribution and pharmacokinet-
ics were studied after intratracheal delivery, and the results
proved that the shell crosslinking has a key role in control-
ling the rate of extravasation from the lungs; SCKs were
retained almost twice than their uncrosslinked counterparts.
Fig. 11 Structure of the PCL-PEEP star-shaped copolymer and micelles’ formation
Fig. 12 Structure of the PBEP-b-PBYP-g-PEG block terpolymer (adapted from [103])
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Micelles prepared by the use of both synthetic and
natural polymers are gaining importance. Dai et al. [104]
prepared micelles from a cellulose-g-PLA copolymer by
the nanoprecipitation method and used them to encap-
sulate betulinic acid (BA). The micelles were spherical in
shape with sizes ranging from 100 to 170 nm. The in
vitro release tests showed that the BA release depended
on the amount of PLA in the copolymer; higher
amounts of PLA led to a more sustained release, without
a less accentuated initial burst. The in vitro cytotoxicity
tests carried out on A549 and LLC cell lines showed that
the bare micelles do not elicit any cytotoxic response,
contrarily to what was observed with the BA-loaded
micelles. Moreover, the BA-loaded micelles had a higher
anti-cancer activity when compared with the free drug.
The in vivo tests conducted on a mouse tumor xenograft
model revealed that the micelles were more effective in
promoting tumor inhibition than the BA itself.
Han et al. [105] prepared an amphiphilic copolymer
based on gelatin, PLA, and a lipid moiety, 1,2-dipal-
mitoyl-sn-glycero-3-phosphoethanolamine (gelatin-co-
PLA-DPPE). The micelles were prepared from this
copolymer, by the nanoprecipitation and double emul-
sion methods, and used to encapsulate DOX (in its
salt form). The release of DOX was studied, and the
results showed that the drug release was faster for
pH = 5 than for pH = 7.4. The pH-dependent release
was attributed to the presence of the lipid in the co-
polymer structure. The in vitro cytotoxicity tests, per-
formed on an A549 cell line, indicated that the unloaded
micelles did not have any cytotoxic effect, contrarily to
what was observed with the DOX-loaded micelles. The in
vivo tests also suggested that the DOX-loaded micelles
were effective in suppressing the tumor growth in mice.
Huang et al. [106] prepared PCL-grafted hyaluronic
acid nanoparticles for the oral delivery of anti-cancer
drugs, namely PTX. The PTX-loaded PCL-grafted hya-
luronic acid nanoparticles were prepared by a dialysis
method, followed by coating with chitosan using the
layer-by-layer technique mediated by electrostatic inter-
actions. This DDS is sensitive to pH; in a 3 to 6.8 pH
range the core-shell structure of the nanoparticle is
maintained intact, but with an increase of the pH value
to 7.4, the detachment of the chitosan layer is observed.
The in vitro tests demonstrated that the PTX release is
triggered by the presence of hyaluronidase-1. In the
esophageal squamous carcinoma (EC109) cell line, the
nanoparticles were effectively internalized via a receptor-
mediated endocytosis and rarely uptaken by normal
fibroblast (NIH3T3) cells. Han et al. [107] prepared di-
sulfide crosslinked micelles based on the amphiphilic
hyaluronic acid-b-PCL copolymer for DOX encapsula-
tion (Fig. 13). The in vitro tests reveal that the crosslink-
ing of the micelles’ shell slows the release of DOX in
physiological pH, but in the presence of glutathione
(GSH), a reductive agent found in the cells’ cytoplasm,
the release was noticeably improved. Using a SCC7 cel-
lular line, the in vitro studies showed that the nanoparti-
cles were efficiently internalized by the cells and the
DOX was successfully release at the intracellular level,
by a mechanism based on their binding to the receptor
CD44. The in vivo tests on SCC7-tumor-bearing mice
demonstrated that the DOX-loaded crosslinked micelles
were able to suppress the tumor growth.
Micelles based on methoxyPEG conjugated to denatu-
rated bovine serum albumin were prepared and used as
a carrier for camptothecin (CPT) by Zhang et al. [108].
The unloaded micelles presented sizes of 238 nm,
whereas the diameters of their loaded counterparts were
150 nm. The authors attributed the small size of the
loaded micelles to favorable hydrophobic interactions
that led to more compact micelles. The CPT maximum
loading was ca. 24 %. The cellular uptake tests carried
out on HeLa cells showed that the micelles were easily
uptaken by the cells, even more than the “unmodified”
bovine serum albumin (BSA). Concerning the anti-cancer
performance of the CPT-loaded carriers, it was found that
they possess similar activity to that of free CPT.
Choi et al. [109] prepared micelles based on PEG-
conjugated hyaluronic acid (Fig. 14) and studied the
effect of the presence of PEG in the biodistribution of
the micelles.
The results suggested that the PEGylation of the hyalur-
onic acid micelles decreases the cellular uptake in vitro.
Nevertheless, and more importantly, the cellular uptake
was higher in the overexpressing CD44 tumor cells
(SCC7, MDA-MB-231, and HCT11) than in the normal
fibroblast cells (CV-1). The ex vivo images of the mice’s
organs showed that the PEGylation of the hyaluronic acid
micelles contributes to a significant decrease to their up-
take by the liver, increasing their blood time circulation.
Tests in animal models showed that, after systemic ad-
ministration, the PEG-conjugated hyaluronic acid micelles
were more effectively accumulated in the tumor when
compared with the hyaluronic acid micelles. Driven by
this result, the same group used the micelles as DDS for
CPT [110]. The results evidence that the micelles were
capable of quickly releasing the drug in the presence of
Hyal-1, an enzyme that is found in the intracellular com-
partments of cancer cells. Regarding in vitro cytotoxicity
tests performed on different tumor cell lines, they showed
that, in some cases, the CPT-loaded micelles were more
cytotoxic than free CPT. However, for non-cancerous
cells, the cytotoxicity of the micelles was significantly
lower than that of CPT. The authors attributed this result
to the fact that the CPT-loaded micelles are specifically
uptaken by the tumor cells via receptor (CD44)-mediated
endocytosis, and the drug is quickly released at the
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intracellular level. The in vivo tests demonstrated
that, after the systemic administration of the micelles
in tumor-bearing mice, an inhibition of the tumor
growth was observed.
Another attractive strategy for cancer therapy is the
preparation of micelles based only on natural polymers.
Na et al. [111] prepared micelles using amphiphilic co-
polymers based on glycol chitosan grafted with different
amounts of 5β-cholanic acid. It was found that neither
the size nor the shape was influenced by the amount of
5β-cholanic acid. However, the stability and deformabil-
ity of the micelles decreased upon an increase in the
amount of the acid. From the in vivo studies carried out
on flank tumor-bearing mice, it was figured out that the
micelles showed higher tumor accumulation when com-
pared with glycol chitosan or polystyrene nanoparticles.
The micelles with the highest targeting tumor efficiency
were those obtained from the copolymer bearing 23 % of
5β-cholanic acid. The authors attributed this result to
the good balance between the deformability and stability
of the micelles in vivo.
In the same manner, very recently, Thomas et al. [112]
prepared micelles from hyaluronic acid grafted with 5β-
cholanic acid with the aim of developing DDS with tar-
geting properties to the CD44 overexpressing cells. For
micelles formulated with a PTX, hyaluronic acid 10 %
w/w, the encapsulation efficiency was about 77 %, with a
PTX loading of 7.7 %. The SCC7 cell line, which
expresses the CD44 receptor, was used to evaluate the
cytotoxicity of the PTX-loaded micelles, and the results
highlight that the cell viability decreased significantly
with an increase in the micelles’ concentration, when
compared to the free drug. The in vivo tests revealed
that the loaded micelles inhibited in a more effective
way the tumor growth, with minimal side effects, when
compared with free PTX.
Implants
Implants are very useful in cancer therapy since they
promote the delivery of the drug in the “right” place and
can provide the drug release over longer periods of time.
This fact avoids the repeated external drug administration,
increasing the patient’s compliance. The implants can be
classified in surgical implants (pre-formed implants
like rods, wafers, meshes), if they have a specific
structure before the implantation, or in injectable
Fig. 13 Structure of the amphiphilic hyaluronic acid-b-PCL copolymer
Fig. 14 Structure of the PEG-conjugated hyaluronic acid
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implants [24, 113]. The polymer implants can be
grouped into three main categories: intratumoral, adju-
vant, and palliative (Fig. 15). Intratumoral implants are
those that are placed directly into the tumor. If the
implant is placed in the tumor after another treat-
ment (e.g., surgery resection or ablation), it is called
adjuvant. Palliative implants are those that are im-
planted subcutaneously or intramuscularly and are
usually used to avoid the repeated injections and im-
prove patient compliance in the late stage of palliative
care [114].
There are already some polymer-based implants in the
market or are under clinical trials, as can be seen in
Table 2.
For localized therapy, besides the PLGA-b-PEG-b-
PLGA, chitosan is another material extensively used in
the development of injectable hydrogels for cancer therapy
[115, 116]. Nevertheless, there is the need to perform
more studies in order to release chitosan-based implants
in the market.
Millirods are another type of implants potentially
usable in the cancer field and have the main function of
reducing the local recurrence rates of tumors when
those are subjected to radiofrequency ablation. PLGA
has been widely used in the preparation of millirods for
this purpose [117–119]. In another approach, PLGA
millirods were developed as DDS for the treatment of
glioblastoma multiforme (GBM) via stereotactic injec-
tion [120]. The millirods were processed by two different
techniques, viz., hot melt extrusion (HME) and injection
moulding (IM), and loaded with disulfiram (DSF). The
results showed that the processing technique influenced
the physical state of DSF in the millirod; in the HME
millirod, the drug was completely amorphous, whereas
in the IM millirods, about 54 to 66 % of the DSF crystal-
linity was preserved. The in vitro cytotoxicity tests, using
a GBM cell line, showed that the 10 wt.% DSF-loaded
HME millirods presented cytotoxicity similar to free
DSF. PLGA in the form of wafers was also tested as
DDS with the same purpose [121].
Fig. 15 Different categories of the implants (adapted from [114])
Table 2 Polymer-based implants used in the treatment and prevention of cancer (adapted from [24])
Polymer Drug Implant form Trade name Administration Therapeutic purpose Stage of development




Used clinically to treat
glioblastoma brain cancer
Polyphosphoester PTX Microparticles Paclimer® Intraperitoneal Advanced ovarian
cancer
Phase I dose escalation trial for
treatment of advanced ovarian cancer
PLGA-b-PEG-b-PLGA PTX Thermosensitive
hydrogel
OncoGel™ Intratumoral Esophageal cancer Phase IIb efficacy trials for treatment
of esophageal cancer
aPoly[(1,3-bis-carboxyphenoxypropane)-co-(sebacic anhydride)]
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In a very recent contribution, Gao et al. [122] developed
an injectable implant based on PLGA, incorporating Fe
powder and DOX that exhibited a liquid-solid transition
when in contact with aqueous solutions. The in vitro re-
lease tests showed that the DOX release was accelerated
in a pH = 5 and when the implant was subjected to an
external alternating current magnetic field (AMF). In turn,
the in vivo tests showed that, upon application of the
AMF, the implant had the ability to convert magnetic
energy into heat, increasing the local temperature in order
to achieve tumor coagulative necrosis. The increase in
temperature also contributed to accelerate the DOX re-
lease, improving the tumor cells’ apoptosis. The real-time
ultrasound and computerized tomography imaging proved
that no leakage of Fe particles occurred.
Other contributions report the use of bioabsorbable poly-
mers like PCL or gelatin in the development of implants.
Yohe et al. [123] prepared 3D superhydrophobic electro-
spun meshes based on PCL and the hydrophobic polymer
dopant poly(glycerol monostearate-co-ε-caprolactone)
(PGC-C18) and tested their potential as local DDS for colo-
rectal cancer cells, using CPT-11 and SN-18 as model
drugs. The release of the drugs can be modulated by chan-
ging the hydrophobicity of the mesh; a slower release is
observed for more hydrophobic meshes. The in vitro cyto-
toxicity tests carried out on a human colorectal (HT-29)
cell line showed that the SN-38-loaded meshes were cyto-
toxic for the cells, contrarily to what was observed with
CPT-11-loaded meshes. Regarding the mechanical per-
formance of the meshes, it was found that these structures
are robust and flexible making them potentially usable in
surgical procedures during colorectal surgery. Moreover,
meshes allow the non-invasive assessment of their loca-
tion and the status of drug delivery by ultrasound.
Recently, in a very interesting approach, Yang et al.
[124] prepared an implantable active-targeting micelle-
in-nanofiber device to be used as DDS for DOX, by the
co-axial electrospinning method. The nanofibers’ core was
formed by a mixture of poly(vinyl alcohol) and micelles
(made from a folate-conjugated PCL-PEG copolymer),
and the shell comprised crosslinked gelatin. The in vitro
cytotoxicity tests showed that the device is non-cytotoxic
either for 4T1 tumor cells or for NIH-3T3 fibroblasts. The
anti-tumor efficacy was evaluated in 4T1 tumor cells, and
the results showed that the nanofibers cause an apoptotic
response for the 4T1 cell population of 69.9 %, this per-
centage being lower than that observed for the cell group
treated with free DOX. The anti-tumor efficacy was tested
with 4T1-tumor-bearing Balb/c mice, and the results
showed that after 21 days, the mean volume of the tumors
treated with the nanofibers is smaller than that in which
DOX was delivered intravenously. However, the histo-
logical analysis confirmed that the DOX-loaded nanofibers
induced apoptosis of the cancer cells.
Conclusions
The importance of bioabsorbable polymers in the field
of cancer therapy is undeniable, taking into account the
high number of publications related to the use of these
materials as DDS for anti-cancer drugs. Moreover, there
are already in the market formulations for chemotherapy
treatments making use of bioabsorbable polymers, and
many others are currently under clinical trials. Regarding
the fundamental research, many efforts have been de-
voted to the development of the ideal polymeric DDS,
and although promising results have been obtained,
important research efforts will have to be undertaken in
order to develop optimal and efficient target DDS for
cancer therapy.
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